Clinical Trial on Treatment of Intraventricular Hemorrhage
Status:
Completed
Trial end date:
2008-08-01
Target enrollment:
Participant gender:
Summary
The specific objective of this trial is to determine the lowest dose and dose frequency
possible with the best pharmacokinetic and safety profile and it's ability to remove a blood
clot from the ventricular system.
Phase:
Phase 2
Details
Lead Sponsor:
Johns Hopkins University
Collaborators:
FDA Office of Orphan Products Development Genentech, Inc.